Canadian experience with growing hemp commercially for the last 4 years has convinced many growers that it is better to use a single-purpose cultivar, seed or fiber, than a dual-purpose cultivar. The recent focus of Canadian hemp breeders has been to develop cultivars with high seed yields, low stature (to avoid channeling the plants’ energy into stalk, as is the case in fiber cultivars), early maturation (for the short growing seasons of Canada), and desirable fatty acid spectrum (especially gamma-linolenic acid).
Food and beverage products containing CBD were introduced in the United States in 2017. Similar to energy drinks and protein bars which may contain vitamin or herbal additives, food and beverage items can be infused with CBD as an alternative means of ingesting the substance. In the United States, numerous products are marketed as containing CBD, but in reality contain little or none. Some companies marketing CBD-infused food products with claims that are similar to the effects of prescription drugs have received warning letters from the Food and Drug Administration for making unsubstantiated health claims.
In the 1970s, the taxonomic classification of Cannabis took on added significance in North America. Laws prohibiting Cannabis in the United States and Canada specifically named products of C. sativa as prohibited materials. Enterprising attorneys for the defense in a few drug busts argued that the seized Cannabis material may not have been C. sativa, and was therefore not prohibited by law. Attorneys on both sides recruited botanists to provide expert testimony. Among those testifying for the prosecution was Dr. Ernest Small, while Dr. Richard E. Schultes and others testified for the defense. The botanists engaged in heated debate (outside of court), and both camps impugned the other's integrity. The defense attorneys were not often successful in winning their case, because the intent of the law was clear.
Ten trials have evaluated the efficacy of inhaled Cannabis in chemotherapy-induced N/V.[35-38] In two of the studies, inhaled Cannabis was made available only after dronabinol failure. In the first trial, no antiemetic effect was achieved with marijuana in patients receiving cyclophosphamide or doxorubicin, but in the second trial, a statistically significant superior antiemetic effect of inhaled Cannabis versus placebo was found among patients receiving high-dose methotrexate. The third trial was a randomized, double-blind, placebo-controlled, crossover trial involving 20 adults in which both inhaled marijuana and oral THC were evaluated. One-quarter of the patients reported a favorable antiemetic response to the cannabinoid therapies. This latter study was reported in abstract form in 1984. A full report, detailing the methods and outcomes apparently has not been published, which limits a thorough interpretation of the significance of these findings.
To illustrate how hemp programs can wither without proper support, she pointed to California, where regulators continue struggling to keep up with rules and infrastructure for the more potent (and popular) marijuana industry, from lab tests to license approvals; the state's hemp operators, meanwhile, are still waiting for their official license application to come out.
In the United States, the legality of medical marijuana varies in substantial ways from state to state. There are currently 29 US states with legal medical cannabis laws, as well as the District of Columbia. That leaves 21 states where medical marijuana is entirely prohibited. Marijuana cultivation, possession, and use in any form is illegal at the federal level.
Selective breeding of cannabis plants has expanded and diversified as commercial and therapeutic markets develop. Some growers in the U.S. succeeded in lowering the proportion of CBD-to-THC to accommodate customers who preferred varietals that were more mind-altering due to the higher THC and lower CBD content. Hemp is classified as any part of the cannabis plant containing no more than 0.3% THC in dry weight form (not liquid or extracted form).
^ Jump up to: a b Weinstein A, Livny A, Weizman A (2016). "Brain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans: Evidence from Studies of Adult Users". Current Pharmaceutical Design. 22 (42): 6366–6379. doi:10.2174/1381612822666160822151323. PMID 27549374. 1)The studies reviewed so far demonstrated that chronic cannabis use has been associated with a volume reduction of the hippocampus...3)The overall conclusion arising from these studies is that recent cannabis users may experience subtle neurophysiological deficits while performing on working memory tasks, and that they compensate for these deficits by "working harder" by using additional brain regions to meet the demands of the task.
“Specialty pulp” is the most important component of the hemp industry of the EU, and is expected to remain its core market for the foreseeable future. The most important specialty pulp products made from hemp are cigarette paper (Fig. 16), bank notes, technical filters, and hygiene products. Other uses include art papers and tea bags. Several of these applications take advantage of hemp’s high tear and wet strength. This is considered to be a highly stable, high-priced niche market in Europe, where hemp has an 87% market share of the “specialty pulp” sector (Karus et al. 2000). In Europe, decortication/refining machines are available that can produce 10 t/hour of hemp fiber suitable for such pulp use. North American capacity for hemp pulp production and value-added processing is much more limited than that of Europe, and this industry is negligible in North America.